Shares of Smith & Nephew plc (LON:SN - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,024.15 ($13.63) and traded as high as GBX 1,069.50 ($14.23). Smith & Nephew shares last traded at GBX 1,056.50 ($14.06), with a volume of 1,263,176 shares changing hands.
Smith & Nephew Stock Performance
The firm's 50-day moving average price is GBX 1,044.80 and its two-hundred day moving average price is GBX 1,024.15. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The stock has a market cap of £11.58 billion, a price-to-earnings ratio of 38.04, a PEG ratio of 0.46 and a beta of 0.62.
Smith & Nephew Increases Dividend
The company also recently declared a dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Thursday, March 27th will be given a dividend of $0.23 per share. This is a boost from Smith & Nephew's previous dividend of $0.14. The ex-dividend date is Thursday, March 27th. This represents a dividend yield of 1.61%. Smith & Nephew's payout ratio is presently 104.41%.
Insider Activity
In related news, insider Jeremy (Jez) Maiden bought 1,855 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were bought at an average price of GBX 1,070 ($14.24) per share, with a total value of £19,848.50 ($26,415.36). Also, insider Sybella Stanley bought 3,810 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was bought at an average cost of GBX 1,101 ($14.65) per share, for a total transaction of £41,948.10 ($55,826.59). Corporate insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
